logo-loader
viewAdmedus Ltd

Admedus granted final step for approval of first-in-human study

The first-in-human surgical aortic valve replacement study can now go ahead as planned starting this month.

Admedus Ltd - Admedus receives final step for approval of first-in-human study
Admedus is a structural heart company delivering solutions that help healthcare professionals create life-changing outcomes

Admedus Ltd (ASX:AHZ) has been granted the final step for approval of the first-in-human study by the external competent authority, Federal Agency for Medicines and Health Products (FAMHP) of Belgium.

This means the study can go ahead as planned this month.

Chief executive officer Wayne Paterson said: “Now that we have final approval to commence the study, we can move forward according to our plan with Professor Bart Meuris and his team at the University Hospitals Leuven, Belgium, to perform this important study.

“The study will give us valuable information that will help progress our path to market.”

Renowned heart surgeon

Professor Bar Meuris, a renowned surgeon at the University Hospitals in Leuven, Belgium, is conducting the clinical trial sponsored by Admedus Regen Pty Ltd, a wholly-owned subsidiary of Admedus.

Fifteen patients will be enrolled in the study and will be followed up for six months after receiving implantation of the ADAPT® single-piece 3D aortic valve.

The results from the study are expected to be available between the first quarter of 2021 and the third quarter of 2021.

Milestone payment secured

Admedus recently completed the technology transfer of its unique sterilisation method as part of its ADAPT tissue treatment process to 4C Medical Technologies, Inc.

4C Medical is a Minnesota-based developer of AltaValve, a minimally invasive device for mitral valve repair.

The technology transfer follows 4C Medical validating the process.

4C Medical will now pay an additional $US1 million ($US 0.44 million previously received) to use the technology to sterilise the ADAPT tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValve system device.

Quick facts: Admedus Ltd

Price: 4.2 AUD

ASX:AHZ
Market: ASX
Market Cap: $24.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus Ltd proud to unveil its valves publicly for the first time in London

Admedus Ltd's (ASX:AHZ) CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London. The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business. Paterson says the focus is now firmly on the Adapt...

on 20/11/19

2 min read